Tumor antigen peptide bound to major histocompatibility complex molecule (None)

A tumor antigen presented on a major histocompatibility complex (MHC) molecule refers to a peptide—typically derived from tumor-specific or tumor-associated proteins—that is processed by the antigen processing machinery and displayed on the surface of tumor cells in complex with MHC class I or II proteins[1][2][6]. This peptide-MHC complex is recognized by T cell receptors (TCRs) on cytotoxic or helper T cells, leading to immune-mediated elimination of tumor cells. Cancer cells may evade immune detection by losing MHC expression, altering antigen processing pathways, or reducing antigenicity[3][4][5]. Therapeutic approaches such as checkpoint blockade, TCR-engineered cell therapy, and personalized cancer vaccines aim to enhance recognition of these complexes by the immune system for effective tumor control[6][1].

Other names

Tumor antigen–MHC complexTumor peptide-MHC complexTumor antigen presented by HLA (for humans)Neoantigen–MHC complexCancer antigen–MHC complex

Restoration/enhancement of T cell recognition of tumor antigen-MHC complex Blockade of immune escape mechanisms (e.g., preventing downregulation of MHC, reversing antigen-processing defects) Promotion of immune-mediated lysis of tumor cells presenting specific antigens on MHC